Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
暂无分享,去创建一个
C. Bennett | J. Mckoy | C. Angelotta | M. Tallman | T. Kuzel | A. Evens | S. Trifilio | D. Raisch | D. DeAngelo | M. Wadleigh | F. Giles | J. Kell | J. McKoy
[1] H. Kantarjian,et al. The role of gemtuzumab ozogamicin in acute leukaemia therapy , 2005, British journal of haematology.
[2] I. Bernstein,et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.
[3] A. Trontell. The RADAR project and the FDA. , 2005, JAMA.
[4] I. Bernstein,et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. , 2005, Blood.
[5] Matthew H Samore,et al. The Research on Adverse Drug Events and Reports (RADAR) project. , 2005, JAMA.
[6] A. Trontell. Expecting the unexpected--drug safety, pharmacovigilance, and the prepared mind. , 2004, The New England journal of medicine.
[7] L. Peterson,et al. Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] A. Rohatiner,et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia , 2003 .
[9] E. Estey,et al. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia , 2003, Cancer.
[10] G. Garcia-Manero,et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. , 2003, Leukemia research.
[11] E. Estey,et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. , 2003, Leukemia research.
[12] E. Estey,et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia , 2003, Cancer Chemotherapy and Pharmacology.
[13] P. Richardson,et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. , 2003, Blood.
[14] W. Tissing,et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. , 2003, Blood.
[15] H. Kantarjian,et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes , 2003, Cancer.
[16] E. Estey,et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia , 2002, Cancer Chemotherapy and Pharmacology.
[17] A. Gewirtz,et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease , 2002, Bone Marrow Transplantation.
[18] E. Estey,et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. , 2002, Blood.
[19] G. McDonald,et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. , 2002, Blood.
[20] G. McDonald. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). , 2002, Clinical lymphoma.
[21] P. Richardson,et al. Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell Transplantation , 2001, Acta Haematologica.
[22] E. Estey,et al. Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation , 2001, Cancer.
[23] I. Bernstein,et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] X. H. Chen,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] A. Wood,et al. Thrombotic thrombocytopenic purpura and clopidogrel--a need for new approaches to drug safety. , 2000, The New England journal of medicine.
[26] E. Estey,et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia , 2002, Cancer Chemotherapy and Pharmacology.